ADIAL PHARMACEUTICALS, INC.

ADIL

Explore Our Financial Data > Companies > ADIAL PHARMACEUTICALS, INC.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
ADIL
CIK0001513525
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE, VA, 22901
Website adialpharma.com
Phone434-422-9800
CEOCary J. Claiborne
Employees20

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
RevenueN/A
Pre-Tax Income$-8.95 million
Net Income$-8.95 million
Net Income to Common$-8.95 million
EPS$-1.37
View All
Balance Sheet
Cash$2.37 million
Assets$3.45 million
Liabilities$1.32 million
Common Equity$2.13 million
Liabilities & Equity$3.45 million
View All
Cash Flow Statement
Net Income$-8.95 million
Cash From Operating Activities$-6.88 million
Cash From Investing Activities$150,000.00
Cash From Financing Activities$4.07 million
Change in Cash$-2.66 million
View All
Calculations
NOPAT$-6.09 million
EBITDA$-8.61 million
Price to EarningsN/A
Price to Book$1.00
ROE-217.01%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

Engages with Cytel’s Machine Learning Technology on Data Analysis and Phase 3 Trial DesignGLEN ALLEN, Va., June 11, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing precision treatments for addiction and related disorders, today announced progress in the design and planning of its upcoming Phase 3 trial evaluating AD04, its lead investigational therapy for Alcohol Use Disorder (AUD). A

Article Link

EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Wednesday announced progress in the design and planning of its upcoming Phase 3 trial evaluating AD04, the company's lead investigational genetically targeted, serotonin-3 receptor antagonist, a therapeutic agent for Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 8 drinks/day). As part of its Phase 3 trial preparation, Adial engaged Cytel Inc., a provider of data science and advanced statistical methodologies for clinical trials,

Article Link

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2025. Cary Claiborne, CEO of Adial Pharmaceuticals, commented, “We made meaningful progress during the first quarter of 2025, completing found

Article Link

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar MarketGlen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received a six-figure development milestone payment from Adovate, LLC,

Article Link

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

Meeting to Take Place on July 25, 2025 Meeting’s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the FDA has granted Adial’s request for an End of Phase 2 meeting to discuss Adial’s pr

Article Link